Schering-Plough licenses hepatitis B drug
Shares of Valeant Pharmaceuticals and Metabasis Technologies jumped late Wednesday after they announced that Schering-Plough had licensed the experimental pradefovir for chronic hepatitis B. Valeant licensed the drug from Metabasis six years ago. Both companies will earn an up-front payment along with a schedule of milestones.
"Pradefovir has the potential to offer improved treatment options for patients with chronic hepatitis B, a serious blood-borne infection affecting some 400 million people worldwide," said Dr. Robert Spiegel, chief medical officer of Schering-Plough Research Institute.
- read the release on the deal
- here's the report on the licensing deal from TheStreet.com
Related Articles:
Valeant hep C drug fails pivotal trial, again. Report
FDA OK's Valeant's Zelapar for Parkinson's. Report
Schering-Plough's turnaround plan may include buyouts. Report
Be the first to comment
More stories about buyouts Phase III chief medical officer milestones hepatitis B Parkinson's Valeant Pharmaceuticals
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
